Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065637 · ClinicalTrials.gov registry record · Phase 3
Once Weekly Parathyroid Hormone for Osteoporosis
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT00065637 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 50 participants.
The verdict
NCT00065637, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis. This study will evaluate the safety and effectiveness of PTH when given once a week.
Interventions
- DRUG Teriparatide
- DRUG Placebo teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065637
The ClinicalTrials.gov registry entry for NCT00065637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Teriparatide is the first listed.
NCT00065637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065637 about?
NCT00065637 is a clinical study titled "Once Weekly Parathyroid Hormone for Osteoporosis". Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis. This study will evaluate the safety and effectiveness of PTH when given once a week.
What is the current status of trial NCT00065637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2003-12. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00065637?
The interventions under investigation include: Teriparatide (DRUG), Placebo teriparatide (DRUG).
Who is sponsoring clinical trial NCT00065637?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.